

Supplementary Table 5. Univariate analysis for OS and PFS in HER2-negative and -positive by the Kaplan-Meier method

Variable	OS, mon, median ± SD	95% CI, mon	p value	PFS, mon, median ± SD	95% CI, mon	p value
HER2-negative^a						
Prechemotherapy NLR			0.002			0.006
≤ 3.0	12.13 ± 0.88	10.40–13.87		6.53 ± 0.70	5.16–7.91	
> 3.0	9.30 ± 0.78	7.77–10.83		4.43 ± 0.91	2.66–6.20	
HER2-positive^b						
Prechemotherapy NLR			0.105			0.450
≤ 3.0	15.73 ± 1.65	12.51–18.96		8.73 ± 1.11	6.55–10.91	
> 3.0	13.53 ± 3.56	6.55–20.52		6.20 ± 3.02	0.29–12.11	

OS, overall survival; PFS, progression-free survival; HER, human epidermal growth factor receptor; SD, standard deviation; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio.

^aThere were 161 HER2-negative patients. Among them 109 patients were NLR ≤ 3.0 (102 patients died) and 52 patients were > 3.0 (48 patients died).

^bThere were 32 HER2-positive patients. Among them 19 patients were NLR ≤ 3.0 (18 patients died) and 13 patients were NLR > 3.0 (11 patients died).